Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0H2JP
|
|||
Former ID |
DNCL003035
|
|||
Drug Name |
Buprenorphine + naloxone
|
|||
Synonyms |
Buprenorphine/naloxone; [5 ,7 (S)]-17-(Cyclopropylmethyl)- -(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy- -methyl-6,14-ethenomorphinan-7-methanol; SCHEMBL18085614; Buprenorphine 10 mg/ml in Methanol; Buprenorphine 01 mg/ml in Methanol; ALKS5461
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Opioid dependence [ICD-11: 6C43.2Z] | Approved | [1] | |
Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 3 | [2] | ||
Company |
Orexo
|
|||
Structure |
Download2D MOL |
|||
Formula |
C29H41NO4
|
|||
Canonical SMILES |
CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O
|
|||
InChI |
1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29?/m1/s1
|
|||
InChIKey |
RMRJXGBAOAMLHD-MLLHIGKASA-N
|
|||
CAS Number |
CAS 52485-79-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Opioid receptor mu (MOP) | Target Info | Agonist | [3] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Estrogen signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Enkephalin release | ||||
Pathway Interaction Database | IL4-mediated signaling events | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | TCR Signaling Pathway | |||
GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | ||||
Opioid Signalling | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 2 | ClinicalTrials.gov (NCT02158533) A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study. U.S. National Institutes of Health. | |||
REF 3 | Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.